ICER Chief Scientific Officer Bradt Brings Pharma Perspective
Executive Summary
Pamela Brandt joins health technology assessment group after stints at Aegerion, Astellas and Abbott Labs.
You may also be interested in...
Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
Public statements by Novartis and AveXis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
ICER’s ‘Unsupported Price Increase’ Report Due This Fall
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.